Literature DB >> 12480669

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature.

K Warnatz1, H H Peter, M Schumacher, L Wiese, A Prasse, F Petschner, P Vaith, B Volk, S M Weiner.   

Abstract

BACKGROUND: Immunosuppressive treatment of rheumatic diseases may be associated with several opportunistic infections of the brain. The differentiation between primary central nervous system (CNS) involvement and CNS infection may be difficult, leading to delayed diagnosis.
OBJECTIVE: To differentiate between CNS involvement and CNS infection in systemic rheumatic diseases. METHODS AND
RESULTS: Three patients with either longstanding or suspected systemic rheumatic diseases (systemic lupus erythematodes, Wegener's granulomatosis, and cerebral vasculitis) who presented with various neuropsychiatric symptoms are described. All three patients were pretreated with different immunosuppressive drugs (leflunomide, methotrexate, cyclophosphamide) in combination with corticosteroids. Magnetic resonance imaging of the brain was suggestive of infectious disease, which was confirmed by cerebrospinal fluid analysis or stereotactic brain biopsy (progressive multifocal leucoencephalopathy (PML) in two and nocardiosis in one patient). DISCUSSION: More than 20 cases of PML or cerebral nocardiosis in patients receiving corticosteroids and cytotoxic drugs for rheumatic disease have been reported. The clinical aspects of opportunistic CNS infections and the role of brain imaging, cerebrospinal fluid analysis and stereotactic brain biopsy in the differential diagnosis are reviewed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12480669      PMCID: PMC1754279          DOI: 10.1136/ard.62.1.50

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  72 in total

1.  Wegener granulomatosis: MR imaging findings in brain and meninges.

Authors:  J M Murphy; B Gomez-Anson; J H Gillard; N M Antoun; J Cross; J D Elliott; M Lockwood
Journal:  Radiology       Date:  1999-12       Impact factor: 11.105

Review 2.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

Review 3.  Clinical presentation, diagnosis and therapy of progressive multifocal leukoencephalopathy.

Authors:  N S Brink; R F Miller
Journal:  J Infect       Date:  1996-03       Impact factor: 6.072

4.  Progressive multifocal leukoencephalopathy and cryptococcal meningitis with systemic lupus erythematosus and thymoma.

Authors:  D Malas; S Weiss
Journal:  Ann Neurol       Date:  1977-02       Impact factor: 10.422

5.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

Review 6.  [Infectious inflammatory diseases of the central nervous system from the neurological and internal medicine viewpoint].

Authors:  H W Pfister; D Eichenlaub
Journal:  Internist (Berl)       Date:  2001-07       Impact factor: 0.743

7.  Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy.

Authors:  L P Weiner; R M Herndon; O Narayan; R T Johnson; K Shah; L J Rubinstein; T J Preziosi; F K Conley
Journal:  N Engl J Med       Date:  1972-02-24       Impact factor: 91.245

8.  Acute, chronic, and recurrent varicella zoster virus neuropathy without zoster rash.

Authors:  R J Fox; S L Galetta; R Mahalingam; M Wellish; B Forghani; D H Gilden
Journal:  Neurology       Date:  2001-07-24       Impact factor: 9.910

9.  Progressive multifocal leukoencephalopathy: clinical and radiographic features.

Authors:  L B Krupp; R B Lipton; M L Swerdlow; N E Leeds; J Llena
Journal:  Ann Neurol       Date:  1985-04       Impact factor: 10.422

10.  The incidence and prognosis of central nervous system disease in systemic lupus erythematosus.

Authors:  J T Sibley; W P Olszynski; W E Decoteau; M B Sundaram
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

View more
  23 in total

Review 1.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Ozgür Yaldizli; Norman Putzki
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  A case of tuberculous meningoencephalitis in a patient with Behçet's disease.

Authors:  Alexios Iliopoulos; Simeon Kedikoglou; Stefanos Laxanis; Spiros Kourouklis; Evagelos Katsaros
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

Review 4.  Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Authors:  Jiwon Oh; Paul W O'Connor
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

Review 5.  Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.

Authors:  Jiwon Oh; Paul W O'Connor
Journal:  Ther Adv Neurol Disord       Date:  2014-09       Impact factor: 6.570

Review 6.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

7.  JC virus agnoprotein inhibits in vitro differentiation of oligodendrocytes and promotes apoptosis.

Authors:  Nana Merabova; Dorota Kaniowska; Rafal Kaminski; Satish L Deshmane; Martyn K White; Shohreh Amini; Armine Darbinyan; Kamel Khalili
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 8.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

9.  Review of teriflunomide and its potential in the treatment of multiple sclerosis.

Authors:  Clemens Warnke; Gerd Meyer zu Hörste; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

10.  Cerebral involvement in a patient with Goodpasture's disease due to shortened induction therapy: a case report.

Authors:  Christoph Preul; Jens Gerth; Sebastian Lang; Christoph Bergmeier; Otto W Witte; Gunter Wolf; Christoph Terborg
Journal:  J Med Case Rep       Date:  2009-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.